文献速递免疫规划

15价肺炎球菌多糖结合疫苗(PCV15)的免疫原性差异:基于疫苗剂量、免疫途径和小鼠品系

Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
PubMed 文献 · Vaccine · 2017-01-10

本研究在小鼠中评估15价肺炎球菌结合疫苗(PCV15),确定每株多糖0.4μg(6B为0.8μg)为后续研究的最佳剂量,并比较四种小鼠品系经腹腔或肌内免疫后的抗体应答。所有品系对15种血清型均应答,但6B、23F和33F应答较低;腹腔途径在Balb/c、C3H和SW中多数血清型抗体滴度更高,CD1对途径不敏感。

要点

  • PCV15最佳剂量为每株多糖0.4μg(6B为0.8μg)。
  • 所有小鼠品系对疫苗15种血清型均产生应答。
  • 腹腔免疫在Balb/c、C3H和SW中多数血清型抗体滴度更高。

核心结论

  • 鉴于抗体应答随小鼠品系和免疫途径不同而存在差异,在进入临床试验前应在多种动物模型中评估肺炎球菌疫苗以确定最佳配方。

研究设计与样本

  • 临床前小鼠研究:先以Balb/c小鼠评估PCV15不同剂量,再选Balb/c、C3H/HeN、CD1和Swiss Webster(SW)四种品系经腹腔(IP)或肌内(IM)途径免疫,用ECL法测IgG、MOPA测功能性抗体。

主要发现

  • 所有评估的小鼠品系对疫苗所含15种血清型均产生应答,但小鼠对6B、23F和33F血清型的应答倾向于较低。
  • 腹腔免疫途径使Balb/c、C3H和SW中多数血清型的抗体滴度更高;CD1小鼠对多数血清型无论免疫途径如何应答倾向相似。
  • 评估功能性抗体活性时,四种小鼠品系呈现相似趋势。

关键数值与推荐

  • 最佳疫苗剂量确定为每株肺炎球菌多糖0.4μg(6B为0.8μg)。
  • 该多糖剂量基于多重电化学发光(ECL)法测定的抗体水平、CRM197肽体外刺激后的T细胞应答及肺炎球菌攻击保护力选定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pneumococcal disease continues to be a medical need even with very effective vaccines on the market. Globally, there are extensive research efforts to improve serotype coverage with novel vaccines; therefore, conducting preclinical studies in different animal models becomes essential. The work presented herein focuses on evaluating a 15-valent pneumococcal conjugate vaccine (PCV15) in mice. Initially we evaluated several doses of PCV15 in Balb/c mice. The optimal vaccine dose was determined to be 0.4μg per pneumococcal polysaccharide (PS) (0.8μg of 6B) for subsequent studies. This PS dose was chosen for PCV evaluation in mice based on antibody levels determined by multiplexed electrochemiluminescent (ECL) assays, T-cell responses following in vitro stimulation with CRM197 peptides and protection from pneumococcal challenge. We then selected four mouse strains for evaluation: Balb/c, C3H/HeN, CD1 and Swiss Webster (SW), immunized with PCV15 by either intraperitoneal (IP) or intramuscular (IM) routes. We assessed IgG responses by ECL assays and functional antibody activity by multiplexed opsonophagocytic assays (MOPA). Every mouse strain evaluated responded to all 15 serotypes contained in the vaccine. Mice tended to have lower responses to serotypes 6B, 23F and 33F. The IP route of immunization resulted in higher antibody titers for most serotypes in Balb/c, C3H and SW. CD1 mice tended to respond similarly for most serotypes, regardless of route of immunization. Similar trends were observed with the four mouse strains when evaluating functional antibody activity. Given the differences in antibody responses based on mouse strain and route of immunization, it is critical to evaluate pneumococcal vaccines in multiple animal models to determine the optimal formulation before moving to clinical trials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Caro-Aguilar I, Indrawati L, Kaufhold RM, et al. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. Vaccine. 2017. PMID: 28087148. doi:10.1016/j.vaccine.2016.12.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。